Table 2.
All tested patients: Overlap Propensity Score-Weighted Characteristics a a Reported are either weighted proportions (for categorical variables) or weighted means (for numeric variables)
| Non- HCW | HCW | |
|---|---|---|
| Count | 66764 | 6145 |
| Race | ||
| Asian | 2.3 | 2.3 |
| Black | 17.9 | 17.9 |
| Other | 8 | 8 |
| White | 71.8 | 71.8 |
| Male | 25.1 | 25.1 |
| Non-Hispanic | 90.2 | 90.2 |
| Smoking | ||
| Current Smoker | 3.7 | 3.7 |
| Former Smoker | 31.7 | 31.7 |
| No | 64.6 | 64.6 |
| Unknown | 0 | 0 |
| Age | 43.38 | 43.38 |
| Exposed to COVID-19 | 58.1 | 58.1 |
| Family member with COVID-19 | 0.1 | 0.1 |
| Cough | 34.4 | 34.4 |
| Fever | 18 | 18 |
| Fatigue | 11.7 | 11.7 |
| Sputum production | 0.9 | 0.9 |
| Flu-like symptoms | 7.3 | 7.3 |
| Diarrhea | 12.7 | 12.7 |
| Loss of appetite | 4.3 | 4.3 |
| Vomiting | 8.7 | 8.7 |
| Asthma | 22.9 | 22.9 |
| Coronary artery disease | 4.6 | 4.6 |
| Transplant history | 0.5 | 0.5 |
| Connective tissue disease | 3.4 | 3.4 |
| Inflammatory Bowel Disease | 2.1 | 2.1 |
| Influenza vaccine | 79.2 | 79.2 |
| Pneumococcal polysaccharide vaccine | 11.3 | 11.3 |
| Pre-testing platelets | 240.05 | 240.05 |
| Pre- testing Aspartate Aminotransferase | 23.87 | 23.87 |
| Pre- testing Chloride | 101.05 | 101.05 |
| Pre- testing Creatinine | 0.92 | 0.92 |
| Pre-testing Hematocrit | 39.48 | 39.48 |
| Pre- testing Potassium | 4.09 | 4.09 |
| Nonsteroidal Anti-inflammatory Drugs | 20.4 | 20.4 |
| Steroids | 17.4 | 17.4 |
| Carvedilol | 0.9 | 0.9 |
| Angiotensin Converting Enzyme inhibitor | 6.7 | 6.7 |
| Angiotensin Receptor Blocker | 4.9 | 4.9 |
| Melatonin | 1.2 | 1.2 |
| Population Per Square Kilometer | 2.92 | 2.92 |
| Median Income (thousands of dollars) | 68.20 | 68.20 |
| Body Mass Index | 2.92 | 2.92 |
| Final Result = Positive Test for SARS-CoV-2 | 7.7 | 8.9 |
| Odds Ratio (95% Confidence Interval) | 1.17 (0.99, 1.38) |